Endo Pharmaceuticals to Relocate From Chadds Ford, Pa., to New Facilities in Malvern Pennsylvania-based Company Moves Its Headquarters to Support Ongoing Growth and Expansion
CHADDS FORD, Pa., Oct. 31, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will relocate its corporate headquarters to a new facility based in Malvern, Pa., by December 2012. The move to a new corporate center, located approximately 18 miles from Chadds Ford, is part of Endo's long-term growth strategy and ongoing transformation into an all-around health solutions company.
With the acquisition of several healthcare, medical device and pharmaceutical companies over the last several years, Endo's new corporate headquarters addresses its continued growth, and will position Endo closer to the heart of the healthcare corridor in Pennsylvania, where nearly 100 other healthcare and life science companies currently reside.
"This move is an important investment in Endo's future," says Dave Holveck, CEO of Endo Pharmaceuticals. "I believe this move will undoubtedly send a positive message of growth, stability and promise to our pharmaceutical and business counterparts."
Endo is committed to a smooth and transparent transition for the Chadds Ford community that helped foster its transformation, and to Malvern, the new community that Endo believes will help sustain its ongoing growth. For more information about the move, visit www.Endo.com.
Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company with a diversified business model, operating in three key business segments – branded pharmaceuticals, generics and devices and services. We deliver an innovative suite of complementary products and services to meet the needs of patients in areas such as pain management, pelvic health, urology, endocrinology and oncology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries American Medical Systems, HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit http://www.endo.com/.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
SOURCE Endo Pharmaceuticals